

MabGenesis Inc.

March 4th, 2020
Business plan, Block Buster TOKYO

We deliver

First-in-class/Best-in-class
"Therapeutic Antibody"
for
Human and Animal Health
using
Phage Display Technology

MabGenesis

1

Phage Display!?

"That's already established technology!"

"Not efficient, end up so much junk ..."

This is not the case!

MabGenesis

2

Upgraded Phage Display Technology
with Three Innovations


1. Amplification
2. Combination
3. Materials: Bone marrow/Spleen

MabGenesis

3

World's best:

- Anti-EGF receptor mAbs
Greater efficacy than ERBITUX (Cetuximab) in tumor growth suppression in mice




MabGenesis

4

World's first:

- Anti-Integrin A6B4 mAb
Recognizes integrin A6B4 "molecular complex" exerting marked anti-tumor effect in mice



MabGenesis

5

Successfully obtained:

- Anti-CADM 1 /IgSF4 mAb
The world's first mAb against "low immunogenic" molecule, not isolated with other technologies
- Anti-Transferrin Receptor (TFR 1) mAb
TFR1 mAb with highest affinity currently in clinical trial

MabGenesis

6

Our quality Phage Display Technology expands
Target Space to discover;

First-in-class mAbs
✓ molecular complexes
✓ low immunogenicity

Best-in-class mAbs
✓ superior efficacy
✓ affinity
✓ new epitopes




MabGenesis

7

Target markets
Animal health, Diagnostics, Human health

✓ Target 15% of growing markets



MabGenesis

8

Business models

1. Platform: Out-license of mAbs identified by Research Collaboration
2. Pipeline: Out-license of mAbs identified in-house
Cancer, Chronic Pain, Infectious Disease (Pandemics)



Discovery → Pre-clinical → Clinical → Market



MabGenesis

9

Sales growth forecast

- ✓ 2 new research collaborations from 2021
- ✓ 1 pipeline out-license from 2023



MabGenesis

10

Call for investment

We need ¥300M to cover initial cost until 2022



MabGenesis

11

Please join us to change

landscape of therapeutic mAb market
with our cutting-edge innovations

MabGenesis

12

Team: Best of Academia and Industry



Katsuhiro Shinjo, DVM, PhD

CEO
Cornell Vet Col.
Pfizer
Seikagaku
Elanco
Eli Lilly



Gene Kurosawa
PhD

CTO
Associate Professor
Fujita Health U.
Antibody Technology
MedImmune



Kazuhiro Morishita
MD, PhD

Advisor
Professor
Faculty of Medicine,
U of Miyazaki
Cancer biology



Ayami Yamasaki Mai Sugiura



Maki Yoshihama Kumiko Yuji
PhD



Shinichi Koizumi
PhD



Yuichiro Shibasaki
PhD

Partner
NIH
Novartis
Pfizer
Raqualia
AskAt

CBO
Pfizer
SMC lab

MabGenesis

13

Contact

CEO
Katsuhiro Shinjo, DVM, PhD
shinjo_katsuhiro@mabgenesis.com
Mobile : +81-80-6573-1990

MabGenesis

14